Current Therapeutic Research-clinical and Experimental最新文献

{"title":"Tarlatamab and the Future of Immunotherapy: A New Approach to Small Cell Lung Cancer","authors":"Raza Ur Rehman MBBS, Ahmad Furqan Anjum MBBS, Rida Fatima MBBS","doi":"10.1016/j.curtheres.2024.100773","DOIUrl":"10.1016/j.curtheres.2024.100773","url":null,"abstract":"","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100773"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11772990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Adverse Effects and Tolerability of Dietary Ginger Supplementation in Patients With Functional Dyspepsia","authors":"Lemlem Gebremariam Aregawi PhD ,&nbsp;Csiki Zoltan MD, PhD","doi":"10.1016/j.curtheres.2025.100792","DOIUrl":"10.1016/j.curtheres.2025.100792","url":null,"abstract":"<div><h3>Background</h3><div>Functional dyspepsia (FD) is a prevalent upper gastrointestinal disorder characterized by chronic or recurrent symptoms, including epigastric pain, bloating, and nausea. Ginger (<em>Zingiber officinale</em>), a natural dietary supplement traditionally used to relieve gastrointestinal discomfort, has limited evidence regarding its safety and tolerability in patients with FD.</div></div><div><h3>Objective</h3><div>To evaluate the safety, tolerability, and adverse effects of ginger supplementation in patients with FD.</div></div><div><h3>Methods</h3><div>This open-label clinical trial was conducted at the Internal Medicine Outpatient Department, University of Debrecen. This study was conducted in full compliance with the ethical principles outlined in the Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of the University of Debrecen (registry reference number: DE RKEB/IKEB 5622-2020). All participants provided written informed consent prior to their inclusion in the study. Fifty patients with FD were initially enrolled, and 47 participants completed the study. Ginger supplementation was administered at a dose of 1080 mg/d in divided doses over 8 weeks. Adverse effects were assessed weekly through clinical evaluations and self-reports, and tolerability was rated by participants at the end of the trial.</div></div><div><h3>Results</h3><div>The study included 47 patients with FD who completed the trial, with a mean (SD) age of 51.49 (14.64) years. Of the participants, 78.7% were females. Ginger supplementation was well tolerated, with mild and transient adverse effects reported, including bloating (14.9%), heartburn (12.8%), and diarrhea (10.6%). None of these adverse events necessitated discontinuation of the treatment. Tolerability was rated as good or excellent by 87.2% of participants, and no severe adverse events were observed.</div></div><div><h3>Conclusions</h3><div>Preliminary findings suggest ginger is well tolerated and may be a viable complementary dietary therapy, though further research is needed. ClinicalTrials.gov identifier: NCT06313814.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100792"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143935151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of the Accuracy of Thyromental Height Test for Predicting Difficult Laryngoscopy in Obstetric Patients Who Are Candidates for Cesarean Section: An Observational Study","authors":"Saghar Samimi Sadeh MD ,&nbsp;Babak Moayer MD ,&nbsp;Masoomeh Natajmajd MD ,&nbsp;Parisa Kianpour PharmD ,&nbsp;Kousha Farhadi MD ,&nbsp;Mahgol Etezadi PharmD ,&nbsp;Mojgan Rahimi MD ,&nbsp;Farhad Etezadi MD","doi":"10.1016/j.curtheres.2025.100784","DOIUrl":"10.1016/j.curtheres.2025.100784","url":null,"abstract":"<div><h3>Background</h3><div>Pregnant women frequently have face and upper airway edema, which makes managing the airways during anesthesia difficult and increases the risk of mask breathing complications and intubation failure. This necessitates an investigation into the sensitivity of various airway tests in predicting difficult intubation.</div></div><div><h3>Objective</h3><div>To assess the accuracy of the thyromental height test (TMHT) in predicting difficult laryngoscopy in obstetric patients undergoing cesarean section and to compare its effectiveness with other airway assessment methods.</div></div><div><h3>Methods</h3><div>We included a cohort of obstetric patients, approved by the Ethics Committee of Tehran University of Medical Sciences, scheduled for elective cesarean sections. During laryngoscopy, preoperative evaluations of the airway were done. The primary aim was to determine the relationship between TMHT (the distance between mentum and the thyroid cartilage) and the Cormack-Lehane (which categories laryngoscopy view from fully observable vocal cords to nonvisible epiglottis) classification, which indicates the level of difficulty in laryngoscopy.</div></div><div><h3>Results</h3><div>After eligibility assessment, 156 patients entered the study, of which 16 had Cormack-Lehane grades III and IV and were considered difficult laryngoscopy. The TMHT demonstrated a higher Matthews correlation coefficient (0.695), sensitivity (0.75), and specificity (0.96) compared with other tests, suggesting that TMHT has the potential to serve as a dependable predictor of challenging laryngoscopy.</div></div><div><h3>Conclusions</h3><div>The use of TMHT can improve patient outcomes and the preoperative evaluation process, making it a valuable tool for anesthesiologists managing obstetric patients. The TMHT could be considered a complementary tool to existing airway assessment methods, particularly in obstetric patients, due to its high predictive accuracy and ease of use.</div><div>This study is registered at Iranian Registry of Clinical Trial (IRCT) under identifier code of IR.TUMS.SINAHOSPITAL.REC.1399.061.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100784"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143821267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ethnomedicine Knowledge Among Iranian Patients With Gastrointestinal And Liver Disorders: A Cross-Sectional Study","authors":"Fatemeh Sadat Hasheminasab MD,Ph.D ,&nbsp;Yasaman Zamanian MD ,&nbsp;Saiedeh Haji-Maghsoudi Ph.D ,&nbsp;Alireza Bakhshipour MD ,&nbsp;Maryam Azimi MD,Ph.D","doi":"10.1016/j.curtheres.2024.100774","DOIUrl":"10.1016/j.curtheres.2024.100774","url":null,"abstract":"<div><h3>Introduction</h3><div>The role of complementary and alternative medicine (CAM) in healthcare is substantial and frequently overlooked, with widespread use in both developed and developing countries. This study aimed to explore the ethnomedicinal knowledge including prevalence, socio-demographic, and health related characteristics related to gastroenterology and hepatology disorders in Kerman province.</div></div><div><h3>Materials and methods</h3><div>This study included 400 eligible patients attending gastroenterology and hepatology outpatient clinic. Data collection was conducted using various assessment tools, that is, a self-administered demographic and ethnomedicine questionnaire, and quality of life questionnaire.</div></div><div><h3>Results</h3><div>The findings of the present study revealed that 40.3% of the patients surveyed commonly used CAM. Among the participants, 63.4% did not alter their medication intake while using CAM, and 85.7% were satisfied with its effectiveness. The majority of consumers relied on friends and family, making up 41.6% of the sources of information on CAM, with only 14.9% disclosing their CAM usage to physicians. Furthermore, CAM users have a significantly higher level of education, with the physical functioning being a key aspect of QOL.</div></div><div><h3>Conclusion</h3><div>Although the results of this study may not be broadly generalizable, specific points in the findings are still significant. The utilization of CAM treating for gastrointestinal and liver issues is becoming more prevalent among patients in the area. It is essential to educate patients about the real effects of CAM in disease prevention and treatment, particularly considering patient concerns about side effects, and untrustworthy information sources.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100774"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143142208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Randomized, Prospective and Crossover Study, Comparing the Eradication Rate After 10 Days of Concomitant Therapy to Bismuth Quadruple Therapy Among a Sample of the Lebanese Population","authors":"Jad Chidiac MD ,&nbsp;Reine-Marie Kahwaji MD ,&nbsp;Souheil Hallit PharmD, MSc, MPH, PhD ,&nbsp;Yara Yazbeck MD ,&nbsp;Bassem Akiki MD ,&nbsp;Charbel Yazbeck MD","doi":"10.1016/j.curtheres.2025.100791","DOIUrl":"10.1016/j.curtheres.2025.100791","url":null,"abstract":"<div><h3>Background</h3><div>Concomitant therapy and bismuth quadruple therapy are both recommended as first-line treatment regimens for the empiric treatment of <em>Helicobacter pylori</em> infection, especially after the increased resistance to clarithromycin.</div></div><div><h3>Objective</h3><div>Our goal was to compare both treatment regimens among a sample of the Lebanese population to eventually conclude whether one of these therapies has a higher efficacy than the other one as a first- and second-line treatment regimens.</div></div><div><h3>Methods</h3><div>It is a randomized, prospective, and crossover study, started from March 2016 to December 2018. Participants were randomly chosen patients diagnosed with active <em>H pylori</em> through histology. Two groups were then formed randomly and equally: patients in the first group received 10 days of concomitant therapy, whereas patients in the second group received 10 days of bismuth quadruple therapy. Eradication was evaluated by the ¹⁴C urea breath test done 6 weeks after the end of antibiotic use. A negative breath test indicated a successful eradication. All patients with a positive breath test were then given the other treatment regimen for another 10 days and then re-evaluated for eradication in the same manner.</div></div><div><h3>Results</h3><div>Both regimens demonstrated similar efficacy as first-line therapies for <em>H pylori</em> eradication. Among 175 patients receiving concomitant therapy, 160 (91.4%) achieved eradication, whereas in the 174 patients treated with bismuth quadruple therapy, 164 (94.2%) were successfully eradicated (<em>P</em> = 0.306). Among patients requiring second-line treatment, 14 of 15 (93.3%) who failed concomitant therapy were successfully treated with bismuth quadruple therapy, whereas all 10 patients (100%) who failed bismuth therapy achieved eradication with concomitant therapy (<em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Bismuth quadruple therapy and concomitant therapy are both equally effective first-line treatment regimens for the eradication of <em>H pylori</em>. They are also effective if used as second-line treatment regimens for this purpose. Lebanese Clinical Trials Registry identifier: LBCTR2024095653.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100791"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Use of Mobile Health Applications in Palestinian Community Pharmacy Practice","authors":"Ahmed Nouri PharmD, MSc","doi":"10.1016/j.curtheres.2025.100782","DOIUrl":"10.1016/j.curtheres.2025.100782","url":null,"abstract":"<div><h3>Background</h3><div>Mobile health applications have become essential tools in modern healthcare, enabling professionals to access real-time drug information, clinical guidelines, and patient management resources. While globally embraced, the adoption of these apps in resource-limited settings like Palestine remains under-researched, particularly among community pharmacists, who are pivotal to the healthcare system.</div></div><div><h3>Aims</h3><div>This study explores the perceptions, awareness, and challenges faced by Palestinian community pharmacists regarding mobile health applications. It aims to assess the feasibility of integrating these tools into their practice to improve pharmaceutical care and patient outcomes.</div></div><div><h3>Methods</h3><div>A cross-sectional online survey was conducted in 2023 among community pharmacists in Palestine. A self-administered electronic questionnaire was distributed via social media, targeting registered pharmacists. Data were collected using a structured, validated questionnaire addressing demographics, app usage patterns, perceived benefits, and barriers. Descriptive and inferential analyses were performed using SPSS® software, with P-values ≤0.05 considered statistically significant.</div></div><div><h3>Results</h3><div>The study included 400 community pharmacists, predominantly female (65.8%). Pharmacists frequently used information resources for verifying drug interactions (89%) and dosages (98%), citing quick access to reliable information as a major advantage. Barriers included time constraints (92.3%) and concerns about patient trust (77.8%). No significant associations were found between demographics (e.g., gender, years of experience) and perceptions of app usefulness or trust. A strong positive correlation (<em>P</em> &lt; 0.001) was observed between community pharmacists’ support for mobile health applications and their perception of the applications’ reliability. This indicates that pharmacists who perceive mobile apps as reliable are more likely to support their use in practice.</div></div><div><h3>Conclusion</h3><div>Limited app use among Palestinian community pharmacists impacts medication safety, patient trust, and care quality. Adopting mobile tools can improve efficiency, reduce errors, and align pharmacy practice with modern standards, highlighting the need for future research.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100782"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143684679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Cevimeline on Xerostomia in Sjögren's Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","authors":"Mehdi Karimi MD ,&nbsp;Fatemeh Ahmadi Hajikolaei MD ,&nbsp;Fahime Hoseinpour MD ,&nbsp;Seyed-Ali Hashemi MD ,&nbsp;Anita Fatehi MD ,&nbsp;Seyed-Abbas Pakmehr MD ,&nbsp;Niloofar Deravi MD ,&nbsp;Mahdyieh Naziri MSc ,&nbsp;Mohaddeseh Belbasi MD ,&nbsp;Sahar Khoshravesh MD ,&nbsp;Seyed Hossein Vaezzadeh MD","doi":"10.1016/j.curtheres.2024.100770","DOIUrl":"10.1016/j.curtheres.2024.100770","url":null,"abstract":"<div><h3>Background</h3><div>Xerostomia, or dry mouth, is a common and debilitating symptom in patients with Sjögren's syndrome, affecting their quality of life. Although Cevimeline, a muscarinic agonist, has been investigated as a potential treatment, its efficacy and optimal dosage remain uncertain. This study aims to assess the effectiveness of Cevimeline in relieving xerostomia in patients with Sjögren's syndrome by a meta-analysis of randomized clinical trials (RCT).</div></div><div><h3>Method</h3><div>A comprehensive search was conducted across PubMed, Scopus, Cochrane, and Web of Science databases, utilizing Medical Subject Headings terms and keywords related to “cevimeline,” “xerostomia,” and “Sjögren's syndrome” from inception until January 3, 2024. Studies were selected based on predefined inclusion criteria, focusing on clinical trials involving human subjects treated with cevimeline for xerostomia in Sjögren's syndrome. Data extraction was performed systematically, and statistical analysis was conducted using STATA software.</div></div><div><h3>Result</h3><div>This meta-analysis included three RCTs with a total of 302 patients with Sjögren's syndrome (Cevimeline = 187; Placebo = 115). The analysis demonstrated that Cevimeline significantly reduces xerostomia (regarded as salivary flow, mouth dryness) in patients with Sjögren's syndrome with a pooled odds ratio –5.79 (95% CI [–10.55, –1.03]; <em>I</em><strong>²</strong> = 39.6%).</div></div><div><h3>Conclusions</h3><div>In summary, cevimeline significantly increases salivary flow secretion rates in patients with Sjögren's syndrome. With a favorable safety profile at recommended dosages, cevimeline represents a viable therapeutic option for managing xerostomia, particularly in patients with mild to moderate salivary gland destruction.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100770"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11764655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan","authors":"Hiroaki Konishi PharmD ,&nbsp;Hajime Abe MD, PhD ,&nbsp;Noriko Matsumoto ,&nbsp;Yutaka Endo ,&nbsp;Yoshiki Sekijima MD, PhD ,&nbsp;Mitsuharu Ueda MD, PhD ,&nbsp;Yukio Ando MD, PhD","doi":"10.1016/j.curtheres.2025.100793","DOIUrl":"10.1016/j.curtheres.2025.100793","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;Patients with hereditary transthyretin (ATTRv) amyloidosis experience progressive degeneration of the somatic and peripheral nervous system that can impair ambulation, autonomy, and quality of life (QOL). Tafamidis meglumine (tafamidis) is the first pharmacotherapy approved to slow the progression of peripheral neurological impairment in ATTRv amyloidosis and was well tolerated and efficacious in clinical trials; however, longer-term safety in Japanese patients with ATTRv amyloidosis has not been fully elucidated. Consequently, the present study was conducted to understand the safety and efficacy of long-term use (up to 156 weeks) of tafamidis meglumine under postmarketing conditions in Japan.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;This single-arm observational study (conducted from November 2013 to May 2021) included all patients prescribed tafamidis (20 mg/day) for the treatment of ATTRv amyloidosis in routine clinical practice. The observation period was 156 weeks (3 years) following tafamidis initiation (78 weeks [1.5 years] for patients who initiated treatment after May 2018). The outcomes of interest were clinical characteristics of patients, tafamidis utilization patterns, adverse drug reactions (ADRs), serious ADRs (safety analysis set), and efficacy (Neuropathy Impairment Score–Lower Limbs [NIS-LL] score, total QOL [TQOL] score, modified body mass index [mBMI], and ambulatory status; efficacy analysis set).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;div&gt;A total of 400 and 397 patients were included in the safety and efficacy analysis sets, respectively. The mean ± standard deviation (SD) age was 61.5 ± 15.0 years, 65.5% were male, 57.3% were aged ≥50 years at disease onset, 71.0% were from nonendemic areas, and 10.3% had Karnofsky Performance Status 40 to 10. A total of 212 (53.0%) patients were treated with tafamidis for &gt;156 weeks (mean ± SD treatment duration: 120.8 ± 56.4 weeks) and 145 (36.3%) patients discontinued the study, with the reasons for discontinuation (duplicate) being adverse events (&lt;em&gt;n&lt;/em&gt; = 46), hospital transfer (&lt;em&gt;n&lt;/em&gt; = 33), loss to follow-up (&lt;em&gt;n&lt;/em&gt; = 15), insufficient clinical response (&lt;em&gt;n&lt;/em&gt; = 9), and others (&lt;em&gt;n&lt;/em&gt; = 62). ADRs and serious ADRs were reported in 58 (14.5%) and 12 (3.0%) patients, respectively. In the efficacy analysis set, NIS-LL score, TQOL score, mBMI, and ambulatory status after 156 weeks of treatment were comparable to those reported prior to tafamidis initiation.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Implications&lt;/h3&gt;&lt;div&gt;The findings of this study indicate that late-onset cases of ATTRv amyloidosis and those that originate from nonendemic areas may be more prevalent in Japan than historically believed. The safety profile of tafamidis was largely consistent with that obtained from previous research, and no new safety concerns were identified. The efficacy of tafamidis was also demonstrated in the real-world clinical setting.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Clinical trial registration","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100793"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Impact of Frailty Interventions on Older Patients With Frailty","authors":"Miaoyu Zhang,&nbsp;Lingling Zhong","doi":"10.1016/j.curtheres.2024.100769","DOIUrl":"10.1016/j.curtheres.2024.100769","url":null,"abstract":"<div><h3>Background</h3><div>As the global population ages, frailty-marked by diminished physiological reserves and increased vulnerability, poses significant health risks such as falls, hospitalization, and mortality. Exercise therapy, enhancing muscle strength and balance, has shown promise in mitigating frailty's effects, while nursing interventions ensure tailored, comprehensive care. However, the combined impact of these interventions remains underexplored. This study investigates the clinical effectiveness of integrating active exercise with nursing interventions to manage frailty in elderly patients, aiming to improve their physical function and quality of life.</div></div><div><h3>Methods</h3><div>This retrospective study analyzed 100 elderly patients (≥80 years) admitted to our hospital with mild to moderate frailty. Participants were randomly assigned to either a control group (n = 50), receiving a standard exercise program, or an experimental group (n = 50), receiving the same program with personalized interventions under nursing assistance. Assessments were conducted at baseline and at 1, 3, 6, and 12 months. Outcome measures included assessing functional mobility, physical dependence in activities of daily living (ADLs), balance, muscle strength, degree of frailty and patient satisfaction with the nursing care.</div></div><div><h3>Results</h3><div>There were no significant differences in the baseline characteristics between the two groups (<em>P</em> ˃ 0.05). However, both groups exhibited significant improvements from baseline in functional mobility (<em>P</em> &lt; 0.001), physical dependence in ADLs (<em>P</em> &lt; 0.001), balance (<em>P</em> &lt; 0.001), muscle strength (<em>P</em> &lt; 0.001), and degree of frailty (<em>P</em> &lt; 0.001). Importantly, from 3 months onward, the experimental group showed significantly greater improvements in all these parameters compared to the control group (<em>P</em> &lt; 0.001 for each measure). Additionally, patient satisfaction was higher in the experimental group, with a satisfaction rate of 94.0% compared to 72.0% in the control group (<em>P</em> = 0.013).</div></div><div><h3>Conclusions</h3><div>This study demonstrates that combining active exercise with nursing interventions significantly improves physical performance, independence, balance, muscle strength, and reduces frailty in elderly patients. Furthermore, the high levels of patient satisfaction underscore the effectiveness and favorable reception of this intervention. These findings suggest that the implemented interventions can be a valuable approach in improving the overall health and well-being of elderly patients with frailty.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100769"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144068429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Stem Cell Secretome on the Improvement of Diabetic Wound Recovery: A Systematic Review and Meta-Analysis of In Vivo Studies","authors":"Cecep Suhandi MSc ,&nbsp;Gofarana Wilar PhD ,&nbsp;Khaled M. Elamin PhD ,&nbsp;Audry Rahma Dewayani BSc ,&nbsp;Salsabil Ghaliya BSc ,&nbsp;Astriani Abdullah BSc ,&nbsp;Nasrul Wathoni PhD","doi":"10.1016/j.curtheres.2025.100778","DOIUrl":"10.1016/j.curtheres.2025.100778","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic wounds, characterized by their chronic nature, represent a critical challenge for patients with diabetes, often leading to amputation and mortality. Although stem cells show great promise, their use is limited by challenges related to stability and tumorigenicity. The secretome of stem cells, comprising molecules released by these cells, offers a potential alternative to the challenges associated with stem cell therapy and provides a promising solution for diabetic wound healing.</div></div><div><h3>Objective</h3><div>We conducted a systematic review and meta-analysis of relevant preclinical studies to evaluate the effectiveness of stem cell secretomes in treating diabetic wounds.</div></div><div><h3>Methods</h3><div>The protocol registration for this systematic review and meta-analysis was recorded in the PROSPERO database (CRD42023473726). Databases were searched from their inception until November 20, 2023. The quality assessment of the included studies was performed utilizing the CAMARADES 10-item Quality Checklist. Statistical analyses were conducted using a random-effects model to calculate standardized mean differences (SMD) and 95% confidence intervals (CI), with heterogeneity assessed via the <em>I²</em> statistic. The primary outcome evaluated was the wound closure rate, while secondary outcomes included parameters such as the number of fibroblasts, neutrophils, and macrophages.</div></div><div><h3>Results</h3><div>Twenty studies were included, comprising 382 animal subjects, and five of which were eligible for quantitative evaluation in a meta-analysis. The stem cell secretome significantly improved the wound closure rate (SMD = 9.63; 95% CI = 2.01 −17.25; <em>P</em> = 0.01, I² = 76%) and reduced the number of neutrophils (SMD =  −8.47; 95% CI =  −13.05 to −3.90; <em>P</em> = 0.0003) and macrophages (SMD = −5.32; 95% CI = −9.09 to −1.55; <em>P</em> = 0.006).</div></div><div><h3>Conclusion</h3><div>This review suggests that stem cell secretomes have potential as a novel therapeutic strategy for diabetic wound healing, enhancing wound closure rates and reducing inflammation. These findings support the use of stem cell secretomes as a safer and more stable alternative to direct stem cell therapy, but further clinical studies are needed to confirm these results in human patients.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"102 ","pages":"Article 100778"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143526717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}